Clinical trials: Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer, Brain Metastases
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer
This is a multi-center phase III randomized controlled study to assess the efficacy of Gefitinib alone and Gefitinib combination with Pemetrexed/platinum on patients with brain metastasis from non-small cell lung cancer(NSCLC)…
- Conditions
- Non-small Cell Lung Cancer, Brain Metastases, EGFR Mutation
- Trial name
- NCT01951469
- Testing
- Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
The goal of this retrospective real-world study is to evaluate the effectiveness and safety of first-line osimertinib combined with early intracranial stereotactic radiotherapy (SRT) in patients with EGFR-mutant non-small cell…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Osimertinib, Stereotactic Radiation
- Trial name
- NCT07491211
- Testing
- Osimertinib, intracranial stereotactic radiotherapy
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Lung Cancer, Metastatic Cancer
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as temozolomide may make the tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00080938
- Testing
- Temozolomide, Radiation therapy
- Volunteers
- 26 people
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer, Metastatic Cancer
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00238251
- Testing
- gefitinib, temozolomide, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 59 people
- Sponsor
- Swiss Cancer Institute
EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer
Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M
The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.
- Conditions
- EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases
- Trial name
- NCT02972333
- Testing
- AZD9291 80mg oral each day, Radiation therapy
- Volunteers
- 150 people
- Sponsor
- Shandong Cancer Hospital and Institute
Cancer
Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer
To determine if erlotinib given orally along with concurrent whole brain irradiation in lung cancer patients with brain metastases improves median overall survival and enhances local control compared to those treated with WBRT…
- Trial name
- RadEr (NCT01518621)
- Testing
- Radiation, Radiation plus erlotinib
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- Oslo University Hospital
Lung Cancer, Metastatic Cancer
Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery
RATIONALE: Steroid therapy, such as dexamethasone, may reduce swelling, pain, and other symptoms of inflammation and may be effective in treating some of the problems caused by cancer and cancer treatment.
- Trial name
- NCT00403065
- Testing
- dexamethasone, quality-of-life assessment, radiation therapy
- Where
- 70 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Medical Research Council
Lung Cancer, Metastatic Cancer
Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NRR (NCT00280748)
- Testing
- pemetrexed disodium, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Brain Metastases, Non-small Cell Lung Cancer
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Brain metastases, a common complication,occur in 25-40% of patients with non-small cell lung cancer (NSCLC). Whole-brain radiation therapy(WBRT) and Stereotactic Radiosurgery (SRS) are important approaches to the treatment of…
- Trial name
- NCT01688713
- Testing
- Icotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC)
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
According to literature reports, about 16.3%-19% of newly diagnosed NSCLC patients are associated with brain metastasis, and 30%-50% of NSCLC patients will develop brain metastasis during the whole course of the disease.
- Trial name
- NCT04905550
- Testing
- Almonertinib, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chongqing University Cancer Hospital
Brain Metastases From NSCLC
Stereotactic Radiotherapy in Association With Immunotherapy for the Treatment of NSCLC Brain Metastases
The study's primary objective is the evaluation of toxicities reported during RS or HFSRT in patients with brain metastases from NSCLC undergoing immunotherapy (Safety), with particular reference to the rate of symptomatic…
- Trial name
- STRAITLUC (NCT04787185)
- Testing
- Valutation of toxicity
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Brain Metastases, Adult, Brain Tumor - Metastatic
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation…
- Conditions
- Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
- Trial name
- NCT07132190
- Testing
- Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ayal A. Aizer, MD
NSCLC Stage IV, Brain Metastases, Adult
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease…
- Trial name
- NCT06401824
- Testing
- Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
- Where
- 3 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht University Medical Center
Brain Metastases, Adult, Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial
This pilot pragmatic trial evaluates the feasibility of avoiding radiation therapy in patients with brain metastases who demonstrate an intracranial response to systemic therapy-including immunotherapy, targeted therapy, and/or…
- Trial name
- ACTION-Brain (NCT06974370)
- Testing
- Active Surveillance
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Vermont Medical Center
NSCLC, Non-small Cell Lung Cancer
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.
- Trial name
- NCT03535363
- Testing
- Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Brain Metastases From Non-small Cell Lung Cancer
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
The primary objective of this study is to evaluate the efficacy and safety of veliparib and whole brain radiation therapy in adults with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT01657799
- Testing
- Veliparib, Whole brain radiation therapy
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Lung Cancer, Lung Cancer Metastatic
Pembro+Chemo in Brain Mets
The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis.
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Brain Cancer, Cancer
- Trial name
- NCT04964960
- Testing
- Pembrolizumab, Nab paclitaxel, Paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- John L. Villano, MD, PhD
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer.
- Trial name
- NCT00415363
- Testing
- enzastaurin
- Where
- 7 sites in Denmark, Norway and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic…
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01217411
- Testing
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Brain Metastases from Non-small Cell Lung Cancer
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
This is a research study to find out if the new anti-cancer drug Durvalumab combined with radiation therapy to the brain will work in treating brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT04889066
- Testing
- Stereotactic Radiation Therapy, Durvalumab
- Sponsor
- University of Texas Southwestern Medical Center